Phase II Trial of Olaparib and Pembrolizumab in Advanced Uveal Melanoma Initiated
A phase II trial is underway to evaluate the combination of olaparib and pembrolizumab in patients with advanced uveal melanoma.
Indication
Clinical and regulatory intelligence for Uveal Melanoma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.